Instinct Bio raises $150M equity to boost regenerative medicine and longevity platform
Executive summary: Instinct Bio (Nasdaq: BIOT) closed a $150 million equity funding round on July 28, 2026. The funding supplies discretionary capital to expand the company's longevity‑focused regenerative medicine platform and pursue growth opportunities.
Who is involved: Instinct Bio and undisclosed investors participating in the equity placement.
Likely next: The company will allocate the proceeds to R&D, pipeline advancement, and ecosystem scaling over the coming year.
Instinct Bio announced a $150 million equity financing round to fund its regenerative medicine platform and support strategic growth. The proceeds are described as discretionary capital that will be used to scale the company's longevity‑focused ecosystem and capture market opportunities. This financing provides the biotech with immediate resources to advance research and development efforts.
Timeline
- — Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth (GlobeNewswire)
Analysis — what this means
Likely next events
- Instinct Bio expects to deploy the $150 million equity funding over the next 12 months to advance its regenerative medicine platform.
Sectors affected
- Regenerative medicine
- Longevity biotech